Torqur AG, a clinical-stage biotechnology company advancing treatments for oncology and dermatology, and Lonza, a contract development and manufacturing organizations\ (CDMOs), announced an agreement for the clinical supply of bimiralisib, an investigational therapy being explored across multiple indications, with its most advanced program in development for the treatment of actinic keratosis (AK). The collaboration underpins Lonza’s commitment to supporting emerging biotech companies in translating promising science into medicines for patients.
AK is a common pre‑cancerous skin condition caused by chronic sun exposure and represents the leading precursor to cutaneous squamous cell carcinoma. Despite its prevalence, AK is frequently underdiagnosed, underscoring the need for effective therapeutic options. Bimiralisib is Torqur’s lead drug candidate used primarily for oncology indications. This potent oral dual-acting PI3K and mTOR inhibitor is currently under clinical phase II evaluation for the treatment of AK.
Under the agreement, Lonza will provide technology transfer, process optimization, and cGMP manufacturing services for bimiralisib, supporting Torqur with the expertise and flexibility required to advance a high‑potential clinical‑stage program. Manufacturing will be carried out across Lonza’s highly potent active pharmaceutical ingredient facilities in Nansha (CN) and Visp (CH).